DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients

Pharmacogenomics

Volumn 13, Issue 15, 2012, Pages 1701-1710

  Rieck, Mariana ^a   Schumacher Schuh, Artur F ^a,b   Altmann, Vivian ^a   Francisconi, Carolina Lm ^b   Fagundes, Paulo Tb ^b   Monte, Thaís L ^b   Callegari Jacques, Sidia M ^a   Rieder, Carlos Rm ^b   Hutz, Mara H ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

ANKK1; dopamine; DRD2; dyskinesia; haplotype; levodopa; motor fluctuation; Parkinson's disease; pharmacogenetics; polymorphisms

Indexed keywords

DOPAMINE 2 RECEPTOR; LEVODOPA;

ADULT; AGED; ANKK1 GENE; ARTICLE; DISEASE DURATION; DOPAMINE D2 RECEPTOR GENE; DYSKINESIA; ETHNIC DIFFERENCE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATHOGENESIS; RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; DYSKINESIA, DRUG-INDUCED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, DOPAMINE D2;

EID: 84870011434     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.149     Document Type: Article

References (60)

1. Parkinson J. An essay on the shaking palsy. 1817. J. Neuropsychiatry Clin. Neurosci. 14(2), 223-236 (2002).
2. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP. Epidemiology of Parkinson's disease. J. Neurol. 255(Suppl. 5), S18-S32 (2008).
3. Lewis SJ, Caldwell MA, Barker R A. Modern therapeutic approaches in Parkinson's disease. Expert Rev. Mol. Med. 5(10), 1-20 (2003).
4. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116(7), 1744-1754 (2006). (Pubitemid 44033293)
5. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16(3), 448-458 (2001). (Pubitemid 36041148)
6. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1(8007), 345-349 (1977). (Pubitemid 8024416)
7. Denny AP, Behari M. Motor fluctuations in Parkinson's disease. J. Neurol. Sci. 165(1), 18-23 (1999). (Pubitemid 29298075)
8. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch. Neurol. 63(2), 205-209 (2006). (Pubitemid 43261731)
9. Ku S, Glass GA. Age of Parkinson's disease onset as a predictor for the development of dyskinesia. Mov. Disord. 25(9), 1177-1182 (2010).
10. Sharma JC, Bachmann CG, Linazasoro G. Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism Relat. Disord. 16(8), 490-497 (2010).
11. Oliveri RL, Annesi G, Zappia M et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 53(7), 1425-1430 (1999). (Pubitemid 29491932)
12. Kaiser R, Hofer A, Grapengiesser A et al. l-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 60(11), 1750-1755 (2003). (Pubitemid 36737068)
13. Zappia M, Annesi G, Nicoletti G et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch. Neurol. 62(4), 601-605 (2005). (Pubitemid 40489893)
14. Lee JY, Cho J, Lee EK, Park SS, Jeon BS. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease. Mov. Disord. 26(1), 73-79 (2011).
15. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat. 23(6), 540-545 (2004). (Pubitemid 38720604)
16. Hoenicka J, Quinones-Lombrana A, Espana-Serrano L et al. The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine. Biol. Psychiatry 67(1), 3-11 (2010).
17. Huang W, Payne TJ, Ma JZ et al. Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample. Neuropsychopharmacology 34(2), 319-330 (2009).
18. Bontempi S, Fiorentini C, Busi C, Guerra N, Spano P, Missale C. Identification and characterization of two nuclear factor-kB sites in the regulatory region of the dopamine D2 receptor. Endocrinology 148(5), 2563-2570 (2007). (Pubitemid 46997070)
19. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55(3), 181-184 (1992).
20. Martínez-Martín P, Gil-Nagel A, Gracia LM, Gómez JB, Martínez-Sarriés J, Bermejo F. Unified Parkinson's disease rating scale characteristics and structure. The Cooperative Multicentric Group. Mov. Disord. 9(1), 76-83 (1994). (Pubitemid 24022618)
21. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet. 6(4), 577-582 (1997). (Pubitemid 27142107)
22. Long JC, Williams RC, Urbanek M. An E-M algorithm and testing strategy for multiple locus haplotypes. Am. J. Hum. Genet. 56(3), 799-810 (1995).
23. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68(4), 978-989 (2001). (Pubitemid 32289743)
24. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet. 76(3), 449-462 (2005). (Pubitemid 40250525)
25. Jonsson EG, Nothen MM, Grunhage F et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 4(3), 290-296 (1999). (Pubitemid 29292183)
26. Paus S, Seeger G, Brecht HM et al. Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease. Mov. Disord. 19(6), 705-707 (2004). (Pubitemid 39173028)
27. Zhang Y, Bertolino A, Fazio L et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc. Natl Acad Sci. USA 104(51), 20552-20557 (2007).
28. Yang BZ, Kranzler HR, Zhao H, Gruen JR, Luo X, Gelernter J. Association of haplotypic variants in DRD2, ANKK1, TTC12 and NCAM1 to alcohol dependence in independent case control and family samples. Hum. Mol. Genet. 16(23), 2844-2853 (2007). (Pubitemid 350048383)
29. McGuire V, Van Den Eeden SK, Tanner CM et al. Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium. J. Neurol. Sci. 307(1-2), 22-29 (2011).
30. Jomphe C, Tiberi M, Trudeau LE. Expression of D2 receptor isoforms in cultured neurons reveals equipotent autoreceptor function. Neuropharmacology 50(5), 595-605 (2006).
31. Benoit-Marand M, Borrelli E, Gonon F. Inhibition of dopamine release via presynaptic D2 receptors: time course and functional characteristics in vivo. J. Neurosci. 21(23), 9134-9141 (2001). (Pubitemid 33096856)
32. Duan J, Wainwright MS, Comeron JM et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet. 12(3), 205-216 (2003). (Pubitemid 36204418)
33. Hirvonen MM, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol. Psychiatry 9(12), 1060-1061 (2004). (Pubitemid 40065447)
34. Hirvonen MM, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol. Psychiatry. 10(9), 889 (corrigendum) (2005).
35. Hirvonen MM, Lumme V, Hirvonen J et al. C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo. Prog. Neuropsychopharmacol Biol. Psychiatry 33(4), 630-636 (2009).
36. Hirvonen MM, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J. C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse 63(10), 907-912 (2009).
37. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch. Gen. Psychiatry 48(7), 648-654 (1991).
38. Thompson J, Thomas N, Singleton A et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7(6), 479-484 (1997). (Pubitemid 27517576)
39. Pohjalainen T, Rinne JO, Nagren K et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry 3(3), 256-260 (1998). (Pubitemid 28266335)
40. Ritchie T, Noble EP. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem. Res. 28(1), 73-82 (2003). (Pubitemid 36173228)
41. Laruelle M, Gelernter J, Innis RB. D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene. Mol. Psychiatry 3(3), 261-265 (1998). (Pubitemid 28266336)
42. Laakso A, Pohjalainen T, Bergman J et al. The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal l-amino acid decarboxylase in healthy subjects. Pharmacogenet. Genomics 15(6), 387-391 (2005). (Pubitemid 40835079)
43. Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D. Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease. Pharmacogenomics J. 4(5), 291-306 (2004). (Pubitemid 39345133)
44. Dubertret C, Gouya L, Hanoun N et al. The 3 region of the DRD2 gene is involved in genetic susceptibility to schizophrenia. Schizophr. Res. 67(1), 75-85 (2004). (Pubitemid 38117094)
45. Arbouw ME, Van Vugt JP, Egberts TC, Guchelaar HJ. Pharmacogenetics of antiparkinsonian drug treatment: a systematic review. Pharmacogenomics 8(2), 159-176 (2007).
46. Ponce G, Perez-Gonzalez R, Aragues M et al. The ANKK1 kinase gene and psychiatric disorders. Neurotox. Res. 16(1), 50-59 (2009).
47. Koning JP, Vehof J, Burger H et al. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology (Berl.). 219(3), 727-736 (2012).
48. Wang J, Liu ZL, Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 56(12), 1757-1759 (2001). (Pubitemid 32574582)
49. Marsden CD, Parkes JD. "On-off " effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1(7954), 292-296 (1976).
50. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. 20(Suppl. 11), S11-S16 (2005). (Pubitemid 40846906)
51. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson's disease. Neurology 55(11 Suppl. 4), S13-S20; discussion S21-S13 (2000).
52. Fox SH, Lang AE. Levodopa-related motor complications - phenomenology. Mov. Disord. 23(Suppl. 3), S509-S514 (2008).
53. Colosimo C, Martínez-Martín P, Fabbrini G et al. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov. Disord. 25(9), 1131-1142 (2010).
54. Santos NP, Ribeiro-Rodrigues EM, Ribeiro-Dos-Santos AK et al. Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry-informative marker (AIM) panel. Hum. Mutat. 31(2), 184-190 (2010).
55. Cheshire PA, Williams DR. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. J. Clin. Neurosci. 19(3), 343-348 (2012).
56. Fuxe K, Ferré S, Canals M et al. Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J. Mol. Neurosci. 26(2-3), 209-220 (2005).
57. Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog. Neurobiol. 83(5), 293-309 (2007). (Pubitemid 350102747)
58. Hickey P, Stacy M. Adenosine A2A antagonists in Parkinson's disease: what's next? Curr. Neurol. Neurosci. Rep. 12(4), 376-385 (2012).
59. Popat RA, Van Den Eeden SK, Tanner CM et al. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease. Eur. J. Neurol. 18(5), 756-765 (2011).
60. Greenbaum L, Cohen OS, Inzelberg R et al. Association of the adenosine receptor A2A (ADORA2A) gene with l-dopa induced dyskinesia in Parkinson's disease. Mov. Disord. 27(Suppl. 1), S1385 (2012) (Abstract).